HPV Vaccine Refund Expanded to Age 30 Starting June 2026 – Medi-Sfeer News

Starting in June 2026, Belgium will expand reimbursement for the human papillomavirus (HPV) vaccine to cover individuals up to the age of 30, marking a significant expansion of its national immunization policy. This change, announced by Medi-Sfeer and confirmed through official health channels, aims to increase protection against HPV-related cancers by extending vaccine access beyond the current age limit.

The HPV vaccine has long been recognized as a critical tool in preventing cervical cancer and other malignancies caused by the human papillomavirus. According to the Centers for Disease Control and Prevention (CDC), vaccination is most effective when administered before exposure to the virus, which is why initial recommendations focused on adolescents. However, recent research has shown that the vaccine continues to provide substantial benefits for older age groups, supporting the rationale for broadening eligibility.

Data from the CDC indicates that among women aged 20 to 24 who were screened for cervical cancer between 2008 and 2022, rates of precancerous lesions decreased by approximately 80%. This decline is strongly associated with prior HPV vaccination, particularly in individuals immunized between the ages of 12 and 13, who experienced an 87% reduction in cervical cancer incidence compared to unvaccinated peers. These findings underscore the long-term protective effect of the vaccine when administered during adolescence.

While the vaccine was originally approved for females aged 9 to 26, regulatory agencies including the U.S. Food and Drug Administration (FDA) have gradually expanded the authorized age range. As of February 2025, the FDA approved the HPV vaccine for individuals up to age 45, reflecting growing evidence of its safety and efficacy in preventing HPV-related cancers in adults. The vaccine now protects against not only cervical cancer but also anal, penile, vaginal, vulvar and certain head and neck cancers, including oropharyngeal cancer, which is linked to HPV in about 70% of cases.

Belgium’s decision to extend reimbursement to age 30 aligns with evolving public health guidance that emphasizes catch-up vaccination for those who missed earlier opportunities. By removing financial barriers, the policy seeks to improve vaccination coverage across a broader demographic, potentially reducing the future burden of HPV-associated diseases. The expansion will be integrated into the country’s routine immunization and preventive care framework, with implementation beginning in June 2026.

Public health officials continue to stress that while vaccination is most effective at younger ages, individuals up to age 30 can still derive meaningful protection, particularly if they have not been previously exposed to the HPV strains covered by the vaccine. The move reflects a growing trend in European and global health policy to maximize the preventive impact of HPV vaccination through inclusive, evidence-based age extensions.